Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway

Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronically progressive fibrotic pulmonary disease characterized by an uncertain etiology, a poor prognosis, and a paucity of efficacious treatment options. Dexmedetomidine (Dex), an anesthetic-sparing alpha-2 adrenoceptor (α2AR) agonist,...

Full description

Bibliographic Details
Main Authors: Xiaofan Lai, Yingying Lin, Shaojie Huang, Lvya Pu, Qihao Zeng, Zhongxing Wang, Wenqi Huang
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Respiratory Research
Subjects:
Idiopathic pulmonary fibrosis
Dexmedetomidine
Myofibroblasts
ADORA2B
Online Access:https://doi.org/10.1186/s12931-023-02513-3

Internet

https://doi.org/10.1186/s12931-023-02513-3

Similar Items